aluminum fluoride-labeled PSMA

Aluminum fluoride-labeled PSMA refers to a class of radiopharmaceuticals in which a prostate-specific membrane antigen (PSMA) targeting ligand is labeled with the positron-emitting isotope fluorine-18 (^18^F) via an aluminum-fluoride (Al^18^F) chelation method. These agents are used primarily for positron emission tomography (PET) imaging of prostate cancer. The mechanism involves high-affinity binding to the extracellular domain of PSMA, a transmembrane protein highly overexpressed in most prostate cancer cells but with limited expression in normal tissues. Upon intravenous administration, the radioligand binds specifically to PSMA-expressing cells and is internalized, allowing for sensitive and specific detection of primary and metastatic prostate cancer lesions by PET imaging[1][2][3][9]. The Al^18^F labeling approach enables efficient production of ^18^F-labeled tracers with favorable pharmacokinetics and high image resolution due to the physical properties of fluorine-18[1][2]. Multiple variants exist depending on the specific chelator or linker used; common examples include ^18^F-Alf-PSMA-11.

Other names

fluorine-18 aluminum fluoride-labeled PSMAfluorine18 aluminum fluoride-labeled PSMAfluorine 18 aluminum fluoride-labeled PSMA^18^F-AlF-PSMA^18^F-Aluminum fluoride-labeled PSMA ligand